Free Trial

Daina Graybosch Analyst Performance

Analyst at Leerink Partners

Daina Graybosch is a stock analyst at Leerink Partners, covering 14 publicly traded companies across a range of sectors. Over the past year, Daina Graybosch has issued 8 stock ratings, including buy, hold, and sell recommendations. While full access to Daina Graybosch's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Daina Graybosch's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
20 Last 6 Years
Buy Recommendations
57.89% 11 Buy Ratings
Companies Covered
14 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy57.9%11 ratings
Hold36.8%7 ratings
Sell5.3%1 ratings

Out of 19 total stock ratings issued by Daina Graybosch at Leerink Partners, the majority (57.9%) have been Buy recommendations, followed by 36.8% Hold and 5.3% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
92.9% of companies on NASDAQ
13 companies
NYSE
7.1% of companies on NYSE
1 company

Daina Graybosch, an analyst at Leerink Partners, currently covers 14 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
14 companies
100.0%

Daina Graybosch of Leerink Partners specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
7 companies
50.0%
MED - DRUGS
3 companies
21.4%
PHARMACEUTICAL PREPARATIONS
3 companies
21.4%
LARGE CAP PHARMA
1 company
7.1%

Daina Graybosch's Ratings History at Leerink Partners

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Xilio Therapeutics, Inc. stock logo
XLO
Xilio Therapeutics
8/6/2025Initiated Coverage$0.67$2.00Outperform
Adagene Inc. Sponsored ADR stock logo
ADAG
Adagene
8/6/2025Initiated Coverage$1.90$7.00Outperform
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
6/11/2025Initiated Coverage$22.08$12.00Underperform
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
6/2/2025Set Price Target$109.31$112.00
iTeos Therapeutics, Inc. stock logo
ITOS
iTeos Therapeutics
5/14/2025Reiterated Rating$7.85$9.00Market Perform
Affimed stock logo
AFMD
Affimed
5/13/2025Reiterated Rating$0.69$0.39Market Perform
2seventy bio, Inc. stock logo
TSVT
2seventy bio
3/11/2025Reiterated Rating$2.80$5.00Market Perform
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1/13/2025Lower Price Target$99.74$119.00Outperform